The New England Journal Of Medicine - not
The magnitude of this failure is astonishing. According to the Johns Hopkins Center for Systems Science and Engineering, the United States leads the world in Covid cases and in deaths due to the disease, far exceeding the numbers in much larger countries, such as China. And in the United States we have consistently behaved poorly. As the editorial points out, the U. Like many medical journals, The New England Journal of Medicine has remained nonpartisan over the years and has never publicly supported — or condemned — a political candidate. The New England Journal Of MedicineCryoablation uses cold energy delivered through an inflatable balloon to create scar tissue to interrupt unwanted electrical pathways in the heart.
Drug therapy is currently the standard first-line treatment for patients with atrial fibrillation AF ; however, AF recurs in approximately half of patients treated with AADs within a year of initial treatment. AAD usage frequently causes side effects that can lead many patients to discontinue treatment. Progression of AF is associated with a higher rate of cardiovascular admissions, 2 heart failure hospitalization, 3 and mortality, 4 along with a reduced quality of life.
Mediicine A low rate of patient complications occurred when using catheter ablation as a first-line treatment in AF patients who had never received AAD therapy month rate of primary safety events: 1. These findings also were presented in August as a late-breaking clinical trial at the European Society of Cardiology Congress Digital Experience. It is designed to evaluate the safety and effectiveness of the Medtronic cryoablation system to treat recurrent symptomatic PAF in patients who had not previously received AADs for their atrial fibrillation.
The trial enrolled patients at 24 sites in the United States.
A total of patients randomized to cryoablation in treatment arm or AAD therapy 99 in control arm received treatment and were followed for 12 months. A total of patients with symptomatic AF who had not yet received treatment were randomized to first-line AAD therapy in treatment armor first-line cryoballoon-based pulmonary vein isolation in treatment arm. All patients underwent implantation of the Medtronic Reveal LINQ insertable cardiac monitor for the purpose of continuous arrhythmia monitoring.
The primary outcome was measured by the amount of time, after treatment, that it took for patients to experience a recurrence of AF, atrial flutter or atrial tachycardia. Results from this multicenter investigator-initiated trial found that Medtronic cryoablation was superior in maintaining freedom from AF, atrial tachycardia and atrial flutter, with Safety events were low The New England Journal Of Medicine both groups with 4.
Additionally, patients treated with Medtronic cryoablation demonstrated improvements in quality of life and arrhythmic symptoms e. The trial was sponsored by Dr. Jason Andradedirector of electrophysiology and associate professor at University of British Columbia.
You May Like
Christopher Grangerprofessor of medicine, Duke University. The United States FDA recently expanded the indication for Medtronic cryoablation therapy to include treating patients with drug-refractory recurrent, symptomatic persistent atrial fibrillation episode duration less than six monthsin addition to patients with drug-refractory, recurrent, symptomatic paroxysmal AF. In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical The New England Journal Of Medicine for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world. About Medtronic Medtronic plc www. Medtronic employs more than 90, people worldwide, serving physicians, hospitals and patients in more than countries.
Recent Posts
The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission.
Actual results may differ materially from anticipated results. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database of Systematic ReviewsIssue 9. DOI: J Am Coll Cardiol.]
One thought on “The New England Journal Of Medicine”